Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Davids MS, Ryan CE, Lampson BL, Ren Y, Tyekucheva S, Fernandes SM, Crombie JL, Kim AI, Weinstock M, Montegaard J, Walker HA, Greenman C, Patterson V, Jacobson CA, LaCasce AS, Armand P, Fisher DC, Lo S, Olszewski AJ, Arnason JE, Ahn IE, Brown JR. Davids MS, et al. Among authors: kim ai. J Clin Oncol. 2024 Dec 7:JCO2402503. doi: 10.1200/JCO-24-02503. Online ahead of print. J Clin Oncol. 2024. PMID: 39645236
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S, Montegaard J, Patterson V, Weinstock M, Crombie JL, Ng SY, Kim AI, Jacobson CA, LaCasce AS, Armand P, Arnason JE, Fisher DC, Brown JR. Davids MS, et al. Among authors: kim ai. Lancet Oncol. 2021 Oct;22(10):1391-1402. doi: 10.1016/S1470-2045(21)00455-1. Epub 2021 Sep 14. Lancet Oncol. 2021. PMID: 34534514 Clinical Trial.
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
Merryman RW, Redd RA, Taranto E, Ahmed G, Jeter E, McHugh KM, Brown JR, Crombie JL, Davids MS, Fisher DC, Freedman AS, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Jacene H, Park H, Dahi PB, Nieto Y, Joyce RM, Chen YB, Shipp MA, Herrera AF, Armand P. Merryman RW, et al. Among authors: kim ai. Blood Adv. 2023 Sep 12;7(17):4748-4759. doi: 10.1182/bloodadvances.2022007706. Blood Adv. 2023. PMID: 36399518 Free PMC article.
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
Merryman RW, Redd RA, Freedman AS, Ahn IE, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen ED, Kim AI, LaCasce AS, Ng S, Odejide OO, Parry EM, Isufi I, Kline J, Cohen JB, Mehta-Shah N, Bartlett NL, Mei M, Kuntz TM, Wolff J, Rodig SJ, Armand P, Jacobson CA. Merryman RW, et al. Among authors: kim ai. Ann Hematol. 2024 Jan;103(1):185-198. doi: 10.1007/s00277-023-05475-0. Epub 2023 Oct 18. Ann Hematol. 2024. PMID: 37851072 Clinical Trial.
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. Armand P, et al. Among authors: kim ai. Blood. 2019 Jul 4;134(1):22-29. doi: 10.1182/blood.2019000215. Epub 2019 Apr 5. Blood. 2019. PMID: 30952672 Free PMC article. Clinical Trial.
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation.
Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, Herrera AF, Dahi P, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Bsat J, Patel SS, Ritz J, Rodig SJ, Shipp MA, Chen YB, Joyce RM. Frigault MJ, et al. Among authors: kim ai. Blood Adv. 2020 Jan 14;4(1):122-126. doi: 10.1182/bloodadvances.2019000784. Blood Adv. 2020. PMID: 31917843 Free PMC article. Clinical Trial.
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E. Merryman RW, et al. Blood Adv. 2020 Mar 10;4(5):858-867. doi: 10.1182/bloodadvances.2019001355. Blood Adv. 2020. PMID: 32126141 Free PMC article.
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
Merryman RW, Redd R, Jeter E, Wong JL, McHugh K, Reynolds C, Nazzaro M, Varden A, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Dahi PB, Nieto Y, Joyce RM, Chen YB, Herrera AF, Armand P, Ritz J. Merryman RW, et al. Among authors: kim ai. Transplant Cell Ther. 2022 Jan;28(1):32.e1-32.e10. doi: 10.1016/j.jtct.2021.10.010. Epub 2021 Oct 17. Transplant Cell Ther. 2022. PMID: 34670169 Free PMC article. Clinical Trial.
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
Taranto E, Redd R, Jeter E, McHugh K, Crombie JL, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Odejide OO, Dahi PB, Nieto Y, Joyce RM, Chen YB, Bonjoc KC, Chaudhry A, Herrera AF, Armand P, Merryman RW. Taranto E, et al. Among authors: kim ai. Leuk Lymphoma. 2022 Dec;63(12):2912-2917. doi: 10.1080/10428194.2022.2103808. Epub 2022 Aug 7. Leuk Lymphoma. 2022. PMID: 35938581 Free PMC article.
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.
Merryman RW, Michaud L, Redd R, Mondello P, Park H, Spilberg G, Robertson M, Taranto E, Ahmed G, Chase M, Jeter E, Ahn IE, Brown JR, Crombie J, Davids MS, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Salles G, Zelenetz AD, Armand P, Schöder H, Jacene H. Merryman RW, et al. Among authors: kim ai. Hemasphere. 2023 Jan 24;7(2):e826. doi: 10.1097/HS9.0000000000000826. eCollection 2023 Feb. Hemasphere. 2023. PMID: 36713355 Free PMC article.
138 results